May 21, 2009
By:
Sarah Houlton
Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials.
|
May 21, 2009
By:
Brittany Agro
New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.?
|
May 21, 2009
By:
Jill Wechsler
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
|
May 21, 2009
By:
Paul M. Rivard
Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules.
|
January 9, 2008
By:
George Koroneos, Online Content & News Editor
Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees.
|
January 9, 2008
By:
George Koroneos, Online Content & News Editor
IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms.
|
January 9, 2008
By:
George Koroneos, Online Content & News Editor
Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS.
|
December 12, 2007
By:
George Koroneos, Online Content & News Editor
State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer?
|
December 12, 2007
By:
George Koroneos, Online Content & News Editor
Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
